A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors
2020 ◽
Vol 38
(6)
◽
pp. 1815-1825
◽
Keyword(s):
Phase 1
◽